BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Metabolomics" Keyword-tagged Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Integrated metabolomics and metagenomics analysis identifies a unique signature characterizing metabolic syndrome | Wannaiampikul S; Lee B; Chen J; Prentice KJ; Ayansola R; Xu A; Santosa S; Pantopoulos K; Sweeney G; | 41794383 HKAP |
| 2 | Metabolomics 2023 workshop report: moving toward consensus on best QA/QC practices in LC-MS-based untargeted metabolomics | Mosley JD; Dunn WB; Kuligowski J; Lewis MR; Monge ME; Ulmer Holland C; Vuckovic D; Zanetti KA; Schock TB; | 38980450 CHEMBIOCHEM |
| 3 | Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics | Mosley JD; Schock TB; Beecher CW; Dunn WB; Kuligowski J; Lewis MR; Theodoridis G; Ulmer Holland CZ; Vuckovic D; Wilson ID; Zanetti KA; | 38345679 CHEMBIOCHEM |
| 4 | Metabolomics 2022 workshop report: state of QA/QC best practices in LC-MS-based untargeted metabolomics, informed through mQACC community engagement initiatives | Dunn WB; Kuligowski J; Lewis M; Mosley JD; Schock T; Ulmer Holland C; Zanetti KA; Vuckovic D; | 37940740 CHEMBIOCHEM |
| 5 | New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice | Golizeh M; Nam J; Chatelain E; Jackson Y; Ohlund LB; Rasoolizadeh A; Camargo FV; Mahrouche L; Furtos A; Sleno L; Ndao M; | 36590505 CHEMBIOCHEM |
| 6 | Assessment of solid phase microextraction as a sample preparation tool for untargeted analysis of brain tissue using liquid chromatography-mass spectrometry | Reyes-Garcés N; Boyaci E; Gómez-Ríos GA; Olkowicz M; Monnin C; Bojko B; Vuckovic D; Pawliszyn J; | 33433374 CHEMBIOCHEM |
| 7 | Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC-MS based untargeted metabolomics practitioners | Evans AM; O' Donovan C; Playdon M; Beecher C; Beger RD; Bowden JA; Broadhurst D; Clish CB; Dasari S; Dunn WB; Griffin JL; Hartung T; Hsu PC; Huan T; Jans J; Jones CM; Kachman M; Kleensang A; Lewis MR; Monge ME; Mosley JD; Taylor E; Tayyari F; Theodoridis G; Torta F; Ubhi BK; Vuckovic D; | 33044703 CONCORDIA |
| 8 | Functional Characterization of Clinical Isolates of the Opportunistic Fungal Pathogen Aspergillus nidulans. | Bastos RW, Valero C, Silva LP, Schoen T, Drott M, Brauer V, Silva-Rocha R, Lind A, Steenwyk JL, Rokas A, Rodrigues F, Resendiz-Sharpe A, Lagrou K, Marcet-Houben M, Gabaldón T, McDonnell E, Reid I, Tsang A, Oakley BR, Loures FV, Almeida F, Huttenlocher A, Keller NP, Ries LNA, Goldman GH | 32269156 CSFG |
| 9 | Dexamethasone-Induced Perturbations in Tissue Metabolomics Revealed by Chemical Isotope Labeling LC-MS analysis | Dahabiyeh LA; Malkawi AK; Wang X; Colak D; Mujamammi AH; Sabi EM; Li L; Dasouki M; Abdel Rahman AM; | 31973046 CHEMBIOCHEM |
| 10 | Comparison of underivatized silica and zwitterionic sulfobetaine hydrophilic interaction liquid chromatography stationary phases for global metabolomics of human plasma | Sonnenberg RA; Naz S; Cougnaud L; Vuckovic D; | 31439439 CHEMBIOCHEM |
| 11 | Introduction: Overview of Fungal Genomics. | de Vries RP, Grigoriev IV, Tsang A | 29876804 CSFG |
| Title: | New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice | ||||
| Authors: | Golizeh M, Nam J, Chatelain E, Jackson Y, Ohlund LB, Rasoolizadeh A, Camargo FV, Mahrouche L, Furtos A, Sleno L, Ndao M | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/36590505/ | ||||
| DOI: | 10.1016/j.heliyon.2022.e12380 | ||||
| Publication: | Heliyon | ||||
| Keywords: | Biomarker discovery; Chagas disease; Glutamine; Mass spectrometry; Metabolomics; Mouse model; Phenylalanyl-threonine; Proteomics; Pyroglutamyl-glycine; Sex steroids; Taurine; Testis; Testosterone; Trypanosoma cruzi; | ||||
| PMID: | 36590505 | Category: | Date Added: | 2023-01-02 | |
| Dept Affiliation: |
CHEMBIOCHEM
1 Department of Mathematical and Physical Sciences, Concordia University of Edmonton, Edmonton, Alberta, Canada. 2 National Reference Centre for Parasitology, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada. 3 Infectious Diseases and Immunity in Global Health (IDIGH) Program, Research Institute of McGill University Health Centre, Montreal, Quebec, Canada. 4 Drugs for Neglected Diseases initiative, Geneva, Switzerland. 5 Division of Primary Care Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. 6 Chemistry Department, Université du Québec à Montréal, Montreal, Quebec, Canada. 7 Center for Excellence in Research on Orphan Diseases - Fondation Courtois (CERMO-FC), Montreal, Quebec, Canada. 8 Chemistry Department, Regional Centre for Mass Spectrometry, Université de Montréal, Montreal, Quebec, Canada. 9 Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 10 Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada. |
||||
Description: |
The causative agent of Chagas disease (CD), Trypanosoma cruzi, claims thousands of lives each year. Current diagnostic tools are insufficient to ensure parasitological detection in chronically infected patients has been achieved. A host-derived metabolic signature able to distinguish CD patients from uninfected individuals and assess antiparasitic treatment efficiency is introduced. Serum samples were collected from chronic CD patients, prior to and three years after treatment, and subjected to untargeted metabolomics analysis against demographically matched CD-negative controls. Five metabolites were confirmed by high-resolution tandem mass spectrometry. Several database matches for sex steroids were significantly altered in CD patients. A murine experiment corroborated sex steroid perturbation in T. cruzi-infected mice, particularly in male animals. Proteomics analysis also found increased steroidogenesis in the testes of infected mice. Metabolic alterations identified in this study shed light on the pathogenesis and provide the basis for developing novel assays for the diagnosis and screening of CD patients. |
